These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36971659)

  • 21. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
    Toapanta FR; Ross TM
    Immunol Res; 2006; 36(1-3):197-210. PubMed ID: 17337780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
    Myones BL; Ross GD
    Complement; 1987; 4(2):87-98. PubMed ID: 3497773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
    Barel M; Fiandino A; Lyamani F; Frade R
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure of complement receptor (CR) 2 and CR2-C3d complexes.
    Hannan J; Young K; Szakonyi G; Overduin MJ; Perkins SJ; Chen X; Holers VM
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):983-9. PubMed ID: 12440958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of complement receptor 2 in complex with its C3d ligand.
    Szakonyi G; Guthridge JM; Li D; Young K; Holers VM; Chen XS
    Science; 2001 Jun; 292(5522):1725-8. PubMed ID: 11387479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.
    Prodinger WM
    Immunol Res; 1999; 20(3):187-94. PubMed ID: 10741859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
    Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ
    J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.
    Toapanta FR; DeAlmeida DR; Dunn MD; Ross TM
    Immunol Lett; 2010 Mar; 129(1):32-8. PubMed ID: 20064559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
    Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
    J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2.
    Li K; Okemefuna AI; Gor J; Hannan JP; Asokan R; Holers VM; Perkins SJ
    J Mol Biol; 2008 Dec; 384(1):137-50. PubMed ID: 18804116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A crystal structure of the complex between human complement receptor 2 and its ligand C3d.
    van den Elsen JM; Isenman DE
    Science; 2011 Apr; 332(6029):608-11. PubMed ID: 21527715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.
    Badar A; DeFreitas S; McDonnell JM; Yahya N; Thakor D; Razavi R; Smith R; Sacks S; Mullen GE
    PLoS One; 2011 Apr; 6(4):e18275. PubMed ID: 21494666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP
    Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrostatic Steering Accelerates C3d:CR2 Association.
    Mohan RR; Huber GA; Morikis D
    J Phys Chem B; 2016 Aug; 120(33):8416-23. PubMed ID: 27092816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
    J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
    Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
    J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
    Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
    J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CR2 complement receptor.
    Cooper NR; Bradt BM; Rhim JS; Nemerow GR
    J Invest Dermatol; 1990 Jun; 94(6 Suppl):112S-117S. PubMed ID: 2161885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.